Location: United States, Maryland, Rockville
Employees: 11-50
Founded date: 2011
Investors 2
| Date | Name | Website |
| - | Raisol Cap... | raisol.com |
| - | Horizon Te... | horizontec... |
Mentions in press and media 6
| Date | Title | Description |
| 12.11.2024 | Avalo Therapeutics Receives $69.4 Million in Proceeds from the Full Exercise of Private Placement Warrants | Proceeds from the full exercise of warrants issued in the first quarter of 2024 private placement bring the total gross proceeds from the transaction to $185 million Cash runway expected into at least 2027 WAYNE, Pa. and ROCKVILLE, Md., Nov... |
| 28.03.2024 | Avalo signals change in fortunes by snapping up AlmataBio for ex-Lilly inflammatory drug | Avalo Therapeutics is handing over more than $22 million in stock and cash to acquire AlmataBio for a phase 2-ready monoclonal antibody for hidradenitis suppurativa (HS). The anti-IL-1β mAb, dubbed AVTX-009, has its origins at Eli Lilly. Av... |
| 05.05.2022 | Avalo Therapeutics to lay off 33% of staff amidst market struggles and penny stock status | Avalo Therapeutics is continuing to hit bumps in its journey as it is executing a workforce reduction to focus more on its pipeline. The Rockville, MD-based biotech announced that it would be committing to a staff reduct... |
| 17.02.2022 | Avalo Therapeutics shuffles leadership team as the flailing biotech searches for a port in the storm | Mike Cola A badly stumbling public market for biotech has laid waste to small companies in the first weeks of 2022, and now another victim is shuffling the deck. Avalo Therapeutics CEO Mike Cola and CFO Schond Greenway are stepping away fro... |
| 17.09.2021 | Avalo Therapeutics, Inc. Announces Closing of a $31.5 Million Public Offering of Common Stock, Including Proceeds from Exercise of Option to Purchase Additional Shares | WAYNE, Pa. and ROCKVILLE, Md., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (“Avalo” or the “Company”) (Nasdaq: AVTX), a leading clinical-stage precision medicine company that discovers, develops, and commercializes targeted ... |
| 15.09.2021 | Avalo Therapeutics, Inc. Announces Pricing of $27.5 Million Public Offering of Common Stock | WAYNE, Pa. and ROCKVILLE, Md., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (“Avalo” or the “Company”) (Nasdaq: AVTX), a leading clinical-stage precision medicine company that discovers, develops, and commercializes targeted ... |